The company designs and manufactures gold jewelry, specializing in antique and bridal collections, which it sells on a wholesale basis to large national retail chains and independent jewelry stores across India.
The company claims a moat based on design IP and artisan craftsmanship, but financial metrics contradict this; average ROCE of 5% and net margins of 1.7% are extremely low for a 'design-led' business, suggesting it operates as a low-margin commodity processor rather than a value-added brand.
Management has focused on expanding manufacturing capacity and inventory, funded partly by a 55 crore rights issue in 2024, yet these investments have yielded poor returns on equity (3.2%) and negative cash conversion.
The business collapsed as the gap between its 'design-led' narrative and commodity-level margins became an unbridgeable chasm. Management's decision to prioritize their own compensation—proposing 30 crore in salaries against a 18.5 crore profit—drained the company's liquidity while massive related-party gold trading obscured the true health of the balance sheet. As inventory swelled and cash conversion remained deeply negative, the company eventually ran out of working capital, proving that high revenue growth without cash flow is merely a slow-motion liquidation for minority shareholders.
RichFakir rates Ashapuri Gold Ornament Ltd's business quality as mediocre — 43/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Ashapuri Gold Ornament Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Ashapuri Gold Ornament Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Ashapuri Gold Ornament Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →